Core Viewpoint - The company, Crocs, is facing significant challenges as it anticipates a decline in revenue for the third quarter, contrary to previous analyst expectations for growth, leading to a sharp drop in stock price [2][3]. Financial Performance - In the second quarter, Crocs reported a net loss of approximately $428 million, compared to a profit of about $326 million in the same period last year [2]. - Revenue in North America for the same quarter decreased by 6.5% year-over-year [2]. - The company expects third-quarter revenue to decline by 9% to 11% year-over-year, significantly lower than prior growth forecasts [2]. Market Conditions - Consumer spending on non-essential items in the U.S. is cautious, resulting in decreased foot traffic in stores and concerns over rising prices potentially dampening consumer willingness to spend [2]. - There is a projected shift in consumer shoe purchasing preferences from casual to athletic footwear, influenced by upcoming major sporting events such as the 2026 World Cup and the 2028 Los Angeles Olympics [2]. Cost Implications - The company's profitability is expected to be impacted by U.S. tariff policies, with additional costs estimated at $40 million for the second half of the year and potentially reaching $90 million for the entire year [3]. - Crocs plans to mitigate the impact of tariffs through cost-cutting measures and improving supply chain efficiency [3]. Stock Performance - Following the announcement of the revenue decline, Crocs' stock price fell nearly 30% on the day of the report, marking the largest single-day drop in nearly 14 years [2]. - The stock price has decreased from approximately $109 per share at the beginning of the year to around $75, representing a cumulative decline of over 30% [3].

Core Viewpoint - The company Crocs is experiencing significant financial challenges, with a projected decline in revenue for the third quarter, leading to a sharp drop in stock price, marking the largest single-day decline in nearly 14 years [2][3]. Financial Performance - In the second quarter, Crocs reported a net loss of approximately $428 million, compared to a profit of about $326 million in the same period last year [2]. - Revenue in North America for the same quarter decreased by 6.5% year-over-year [2]. - The company anticipates a revenue decline of 9% to 11% for the third quarter, which is significantly lower than previous analyst growth forecasts [2]. Consumer Behavior and Market Trends - The company noted that U.S. consumers are being very cautious with spending on non-essential items, resulting in decreased foot traffic in stores [2]. - Concerns over rising prices may further suppress consumer willingness to spend [2]. - There is an expected shift in consumer purchasing preferences from casual footwear to athletic shoes, driven by upcoming major sporting events such as the 2026 World Cup and the 2028 Los Angeles Olympics [2]. Impact of Tariffs - Crocs indicated that U.S. tariff policies will negatively impact its profitability, with additional costs from tariffs estimated at $40 million for the second half of the year and potentially reaching $90 million for the entire year (approximately 647 million RMB) [3]. - The company plans to mitigate the impact of tariffs through cost-cutting measures and improving supply chain efficiency [3]. Stock Performance - Following the significant drop on July 7, Crocs' stock price saw a slight rebound on July 8, but has fallen over 30% year-to-date, from approximately $109 per share to around $75 per share [3].

Core Viewpoint - Kanghua Biological has undergone a change in control, with its major shareholder Wang Zhentao transferring part of his equity and voting rights to Shanghai Wankexin Biological, raising questions about the company's future direction amid declining performance [1][2]. Group 1: Ownership Change - On July 20, Kanghua Biological announced that Wang Zhentao and his associates plan to transfer 21.91% of their shares and voting rights, with a total transaction value of 1.85 billion yuan [1][2]. - Wang Zhentao is expected to gain approximately 960 million yuan from this transaction, with the breakdown showing direct and indirect benefits from the sale [2]. Group 2: Financial Performance - Kanghua Biological has faced declining financial performance, with revenue growth stagnating and a projected revenue drop of 9.23% to 1.432 billion yuan in 2024 [6]. - The company's net profit peaked at 830 million yuan in 2021 but has since halved, with a forecasted net profit of 399 million yuan for 2024 [6][7]. - The first quarter of 2025 showed a significant decline, with revenue down 56% year-on-year and net profit down 86% [7]. Group 3: Market Position and Competition - Kanghua Biological's core product, the freeze-dried rabies vaccine, has been under pressure due to high production costs, leading to a price disadvantage compared to competitors [8][9]. - The market share of Kanghua's rabies vaccine has decreased, with a 43.83% drop in the number of vaccine batches approved for sale in 2024 [9]. Group 4: Management and Governance - Despite a reduction in employee numbers to 620, the chairman's salary has increased to a five-year high of 2.3745 million yuan, raising concerns about management decisions amid financial struggles [7]. - Wang Zhentao has high levels of pledged shares, indicating financial pressure, with 89.20% of his directly held shares in Kanghua Biological pledged [9][10]. Group 5: Future Prospects with State-Owned Enterprises - The acquisition by Shanghai Wankexin Biological, linked to state-owned enterprises, is seen as a potential turning point for Kanghua Biological, providing new resources and governance improvements [15][20]. - The Shanghai Biomedicine M&A Fund, which has a significant stake in Wankexin, aims to support Kanghua Biological's restructuring and integration within the biopharmaceutical industry [19][20].

Core Viewpoint - The article emphasizes the value and performance of Swiss Military outdoor trail running shoes, highlighting their comfort, durability, and affordability, especially during a promotional buy-one-get-one-free offer at 179 yuan [11][42][100]. Group 1: Product Features - Swiss Military shoes are designed specifically for outdoor activities, providing excellent comfort and support for various foot shapes, particularly for Asian consumers [23][76]. - The shoes feature a lightweight design with breathable materials, ensuring comfort during long outdoor activities [71][78]. - The sole is engineered for durability and traction, suitable for complex terrains, enhancing stability and reducing injury risk [57][60][68]. Group 2: Brand Background - Swiss Military has a long history, established in 1891, initially providing military products and later expanding into outdoor gear [26][30]. - The brand's reputation is built on high-quality materials and craftsmanship, making it a competitive player in the outdoor footwear market [32][40]. Group 3: Market Positioning - The shoes are positioned as a cost-effective alternative to high-end brands, offering similar quality at a significantly lower price point [9][93]. - The promotional strategy of buy-one-get-one-free is aimed at attracting budget-conscious consumers while maintaining product quality [42][100].

Core Viewpoint - The article discusses the popularity of Crocs and similar "holey shoes," highlighting their comfort and convenience despite the associated issues of foot odor and potential fungal infections [3][4][5]. Group 1: Design and Material Issues - Crocs' design, which includes a full-enclosure style, leads to water accumulation and odor retention, particularly in the toe area [15]. - The plastic material used in Crocs does not absorb sweat or allow for breathability, contributing to odor issues when wet [15]. - The lack of absorbent insoles exacerbates the problem, creating a "swamp" effect for wearers with sweaty feet [15]. Group 2: Social and Psychological Factors - Despite the odor issues, many individuals still prefer Crocs for their quick wearability and adaptability to various environments, including wet conditions [22]. - The ability to customize Crocs with decorative charms allows for personal expression, appealing to younger consumers [24]. - The shift in aesthetic preferences among younger generations has led to a growing acceptance of "ugly" fashion items, including Crocs, as a reflection of changing societal values [29][30]. Group 3: Health Considerations - The humid and enclosed environment created by wearing Crocs can lead to fungal infections, as the shoes can become breeding grounds for bacteria [19]. - Recommendations for mitigating foot odor and fungal risks include wearing breathable socks, cleaning shoes regularly, and maintaining foot hygiene [20].

SHEIN's IPO Plans - SHEIN is reportedly planning to shift its IPO focus to Hong Kong, aiming to submit an application to the Hong Kong Stock Exchange soon and complete the IPO within the year [2] - The company's IPO journey has faced multiple setbacks since 2020, including a failed attempt to go public in the U.S. due to geopolitical changes and subsequent adjustments to its corporate structure [2][3] - In 2024, SHEIN's sales are projected to increase by nearly 40% to approximately $10 billion, with overall revenue growth expected to reach 19% to $38 billion, although profits are anticipated to be significantly lower than the company's expectations [3] Birkenstock's Price Increase - Birkenstock plans to raise global prices to offset the impact of a 10% tariff on EU goods imposed by the U.S., with some styles seeing price increases close to 10% [4] - The company reported a revenue of €574.3 million in Q2 2025, a 19% year-over-year increase, with the Americas market growing by 23% [5] - Birkenstock is expanding its presence in Asia, particularly in China, India, and the Middle East, with a focus on online retail [5] Walmart's Restructuring and Layoffs - Walmart plans to lay off approximately 1,500 employees as part of a restructuring effort to simplify operations and reduce costs, primarily affecting its global tech department and e-commerce fulfillment operations [6] - The company will raise prices on certain products starting at the end of May due to increased costs from tariffs, with CEO Doug McMillon stating that the company cannot absorb all tariff pressures [6] - This marks the second round of layoffs for Walmart in 2023, following earlier job cuts in February [6][7] Jacquemus Group Formation - French designer brand Jacquemus has established a holding company, Jacquemus La Maison Mère, marking its transition to a group structure [18] - The new company has an overall valuation of €576.1 million, following a strategic partnership with L'Oréal, which acquired a 10% minority stake in Jacquemus [18][19] Dior's Creative Director Resignation - Maria Grazia Chiuri has resigned as the artistic director of Dior's women's wear, ending speculation about her future [21] - Under her leadership, Dior's sales grew from €2.2 billion in 2017 to €9 billion in 2023, making it one of the fastest-growing brands in the luxury fashion sector [21] ELF Beauty's Acquisition - ELF Beauty announced the acquisition of Hailey Bieber's skincare brand, Rhode, for a total of $1 billion, marking the largest acquisition in ELF's 18-year history [24] - The deal will involve an initial payment of $800 million, with the remaining $200 million contingent on Rhode meeting specific revenue targets from 2025 to 2027 [25] POLA Group's Exit from China - POLA Group has announced the dissolution and liquidation of its wholly-owned subsidiary in China, raising concerns about the potential exit of its ORBIS brand from the Chinese market [26] - The subsidiary has experienced continuous declines in operating and net profits from 2022 to 2024, with 2024 revenue estimated at only 40 million RMB [26]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 POU SHENG INTERNATIONAL (HOLDINGS) LIMITED 寶勝國際（ 控 股 ）有 限公司 （於百慕達註冊成立之有限公司） （股份代號：3813） 二零二五年四月之每月收益公告 本公司為聯交所主板上市公司裕元的子公司。按照國際財務報告準則，裕元被 視為臺灣證交所上市公司寶成工業之子公司。寶成工業根據臺灣證券交易所的 規例規定刊發每月收益公告。 由於裕元於今日公佈其若干綜合財務資料，故本公司根據上市規則第13.09(2)條 及證券及期貨條例第XIVA部刊發本公告，確保及時向投資者提供最新資料。 1 月份：二零二五年四月 承董事會命 主席 邱暉堯 香港，二零二五年五月十二日 於本公告日期，董事會成員包括： 非執行董事 邱暉堯先生（主席）、蔡佩君女士及李義男先生 執行董事 寶勝國際（控股）有限公司（「本公司」）為香港聯合交易所有限公司（「聯交所」）主 板上市公司裕元工業（集團）有限 ...

Group 1 - The junk bond market is experiencing a resurgence after a period of stagnation due to U.S. President Donald Trump's tariff policies, with companies like Golden Goose and Motel One issuing bonds again [1] - Investment activity is primarily increasing in Europe, driven by expectations of quicker interest rate declines and U.S. investors seeking diversification due to tariff impacts [1] - High-risk transaction types, such as dividend recapitalizations and payment-in-kind notes, indicate rising investor demand [1] Group 2 - The high-yield bond market has made a strong comeback, with last week being the busiest of the year, supported by ample market liquidity [2] - European pharmaceutical company Zentiva raised over €500 million (approximately $550 million) for dividend payments, part of a trend among borrowers engaging in similar transactions [2] - Major transactions are in the pipeline, including JPMorgan leading a $6.5 billion debt financing for 3G Capital's acquisition of Skechers [2] Group 3 - Sunoco LP's acquisition of Parkland Corp. will receive $2.65 billion in loan support, while KKR seeks $3.1 billion for its acquisition of OSTTRA [3] - Some market participants remain cautious, recognizing that not all upcoming projects will succeed despite the current wave of activity [3]

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a net profit growth of 44.23 billion, 50.74 billion, and 57.92 billion RMB for the years 2025 to 2027, corresponding to P/E ratios of 15, 13, and 11 respectively [5] Core Insights - The company reported a revenue of 5.353 billion RMB in Q1 2025, a year-on-year increase of 12.34%, while the net profit attributable to the parent company was 762 million RMB, a decrease of 3.25% [2] - The company is experiencing stable orders with short-term profit margins affected by the ramp-up of new factories, but overall performance is in line with expectations [2] - The company has successfully launched new factories in Vietnam, Indonesia, and China to meet the growing demand, with two new shoe factories already operational in Q1 2025 [3] - The gross margin for Q1 2025 was 22.90%, down 5.47 percentage points year-on-year, primarily due to the efficiency ramp-up of new factories [3] - The company is expected to gradually restore its profitability as new factories improve operational efficiency through optimized training mechanisms and the deployment of smart production equipment [3] Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 5.353 billion RMB, reflecting a 12.34% year-on-year growth, while the net profit attributable to the parent company was 762 million RMB, down 3.25% [2] Operational Analysis - The company sold 49 million pairs of sports shoes in Q1 2025, marking an 8.24% year-on-year increase, with a slight growth in average selling price (ASP) [3] - The company’s gross margin was impacted by new factory ramp-ups, but the net profit margin was 14.26%, down 2.30 percentage points year-on-year [3] Market and Client Dynamics - The company is less affected by tariffs due to its Southeast Asian factories using a processing model and local sourcing of over 50% of raw materials in Vietnam [4] - The company is expected to benefit from new client orders, particularly from Adidas, as it continues to expand its customer base despite slower growth from major clients like Nike [4] Profit Forecast and Valuation - The company is projected to achieve net profits of 44.23 billion, 50.74 billion, and 57.92 billion RMB from 2025 to 2027, with corresponding P/E ratios of 15, 13, and 11 [5]

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a net profit growth of 44.23 billion, 50.74 billion, and 57.92 billion RMB for the years 2025 to 2027, corresponding to PE ratios of 15, 13, and 11 times respectively [5] Core Views - The company reported a revenue of 5.353 billion RMB in Q1 2025, a year-on-year increase of 12.34%, while the net profit attributable to the parent company was 762 million RMB, a decrease of 3.25% [2] - The company is experiencing stable orders with short-term profit margins affected by the ramp-up of new factories, but overall performance is in line with expectations [2] - The company is benefiting from a strong customer base, particularly with new clients like Adidas, which is expected to drive growth despite challenges in the broader market [4] Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 5.353 billion RMB, reflecting a 12.34% year-on-year growth. The net profit attributable to the parent company was 762 million RMB, down 3.25% year-on-year, while the non-recurring net profit was 751 million RMB, also down 3.35% [2] Operational Analysis - The company sold 49 million pairs of sports shoes in Q1 2025, an increase of 8.24% year-on-year, with an increase in average selling price (ASP) contributing to order growth. New customer orders have significantly increased, particularly following the partnership with Adidas that began in Q4 2024 [3] - The gross margin for Q1 2025 was 22.90%, a decrease of 5.47 percentage points year-on-year, primarily due to the efficiency ramp-up of new factories. The company plans to enhance operational efficiency through training and the deployment of smart production equipment [3] Market and Client Dynamics - The company is minimally affected by tariffs due to its Southeast Asia factories operating under a processing model, with over 50% of raw materials sourced locally in Vietnam. The company’s production capacity is concentrated in Vietnam and Cambodia, which mitigates the impact of tariff increases announced by the U.S. [4] - The growth strategy relies heavily on new clients like Adidas and On, with strong order momentum expected to continue. The company’s customer acquisition capabilities are highlighted as a key strength, allowing it to achieve rapid growth even as major clients like Nike experience slower growth [4]